The role of radionuclide therapy in medullary thyroid cancer

Maria Rita Castellani, Alessandra Alessi, Giordano Savelli, Emilio Bombardieri

Research output: Contribution to journalArticlepeer-review


In medullary thyroid carcinoma (MTC) the detection of occult metastases is difficult and the prognosis of widespread disease is poor. In recent years several radiopharmaceuticals have become available for the diagnosis of this tumor. None of these tracers, however, has satisfactory diagnostic sensitivity and specificity. Furthermore, only few radiopharmaceutical compounds proved to have clinical value in therapeutic applications. Radionuclide therapy utilizes unsealed radioactive sources in order to deliver selective irradiation to the target organs or cancer lesions. This approach is only clinically indicated when there is a scintigraphic evidence of sufficient tumor uptake and a favorable biodistribution. When these conditions are present, radionuclide therapy can be adopted in MTC patients. Due to the low incidence of this tumor, the poor sensitivity of the available radiopharmaceuticals and their limited indications, the clinical experience in radionuclide therapy of MTC is still limited and there is general agreement among experts that it has only a palliative role. Here we briefly report the main experiences in radionuclide therapy in the past and in recent years. In addition, we summarize the results obtained with 131-IMIBG therapy at the Istituto Nazionale Tumori of Milan, as well as the most important ongoing preclinical and phase I/II trials.

Original languageEnglish
Pages (from-to)560-562
Number of pages3
Issue number5
Publication statusPublished - Sep 2003


  • Medullary thyroid cancer
  • Metaiodobenzylguanidine therapy
  • Nuclear medicine therapy
  • Radionuclide therapy

ASJC Scopus subject areas

  • Cancer Research


Dive into the research topics of 'The role of radionuclide therapy in medullary thyroid cancer'. Together they form a unique fingerprint.

Cite this